ClinicalTrials.gov
public full text
Public Domain
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a direct comparison of AMG 232 combined with trametinib and dabrafenib versus trametinib combined with dabrafenib alone.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors#1408156
- Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma#868715
- Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma#1320265
- Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies#875062
- Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy#1087175
Record · ID 1485831
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive